Sumitomo Pharma Sues to Block Two Copies of Gemtesa Bladder Drug

Sumitomo Pharma Co. filed a trio of federal lawsuit against Apotex Inc. and Intas Pharmaceuticals Ltd. seeking to block proposed copies of the overactive bladder treatment Gemtesa until a patent expires in 15 years.

Urovant Sciences GmbH and Sumitomo Pharma America Inc., subsidiaries of the Japan-based corporate parent, said the dispute with Intas and its Accord Healthcare unit “belongs in Delaware,” but they concurrently filed a complaint Thursday in the US District Court for the Eastern District of North Carolina “out of an abundance of caution,” since Accord is based in Raleigh, N.C.

Sumitomo Pharma filed in the District of ...